Orbit Discovery

About

Orbit Discovery is a peptide drug discovery company based in Oxford, UK, founded by Professors Terry Rabbitts and Graham Ogg. The company specializes in developing therapeutic peptide-based biological drugs and was incorporated on September 1, 2020. It operates from the Schrödinger Building and is recognized for its proprietary peptide synthesis and functional screening platform, which utilizes bead-based technology and DNA tagging to discover new peptide drugs for challenging therapeutic targets. The company offers peptide discovery services across various therapeutic applications, including radionuclide targeting, nucleic acid targeting, targeted protein degradation, and GPCR and TCR targeting. Orbit Discovery maintains a library of over 1 billion peptides, enabling it to address high-value targets in chronic diseases such as metabolic, autoimmune, cardiovascular, oncology, and infectious diseases. As a rapidly growing biotech firm, Orbit Discovery is well-funded and actively engages in industry conferences to showcase its advancements in drug development.